Replies to post #58133 on Biotech Values

[DewDiligence]

>VRTX – there are just better values out there if a portfolio needs an antiviral company. I had VRTX from $9 to somewhere around $44 in October '06.<

I too made money on VRTX in 2006, but I did it on the short side when I thought the valuation got pushed too high from the VX-950 hyping of Dr. Boger (#msg-10763498, #msg-10831428).

Now, at about half the price where I shorted in 2006, the valuation of VRTX is much more attractive in spite of the longer Telaprevir timeline and the gains by would-be competitors. If it gets much lower, I may have to bite. Regards, Dew

p.s. I think IDIX remains the best value in the antiviral arena for the time being, even after the big run-up this month.